
MADRIGAL PHARMACEUTICALS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Madrigal Pharmaceuticals develops therapies for non-alcoholic steatohepatitis (NASH), a liver disease, with its lead product resmetirom targeting thyroid hormone receptor-beta to reduce liver fat and fibrosis.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Kelley Shannon TGeneral Counsel | Sell | $342K | 664at $514.97 | Aug 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MDGL activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.